Circulating Levels of Apelin, GDF-15 and Sarcopenia: Lack of Association in the MAPT Study.
Biomarkers
gait speed
handgrip strength
muscle mass
Journal
The journal of nutrition, health & aging
ISSN: 1760-4788
Titre abrégé: J Nutr Health Aging
Pays: France
ID NLM: 100893366
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
19
6
2022
pubmed:
20
6
2022
medline:
22
6
2022
Statut:
ppublish
Résumé
Apelin and GDF-15 have been proposed as biomarkers of age-related sarcopenia but evidence in human models is scarce. This study aimed to explore the associations between blood apelin and GDF-15 with sarcopenia incidence and the evolution of sarcopenia components over two years in older adults >70 years. Secondary longitudinal analysis of the Multidomain Alzheimer Preventive Trial. Older adults (>70 years) attending primary care centers in France and Monaco. Community. Serum Apelin (pg/mL) and plasma GDF-15 (pg/mL) were measured. Outcomes included sarcopenia defined by the European Working Group on Sarcopenia in Older People (EWGSOP) and its determinants (appendicular lean mass [ALM] evaluated through a Dual-energy X-ray Absorptiometry (DXA) scan, handgrip strength (HGS) and the 4-meter gait speed) measured over 2 years. Linear mixed models and logistic regression were used to explore the longitudinal associations. We included 168 subjects from MAPT (median age=76y, IQR=73-79; 78% women). Serum apelin was not significantly associated with sarcopenia incidence (OR=1.001;95%CI=1.000,1.001;p-value>0.05 in full-adjusted models) nor with ALM (β=-5.8E-05;95%CI=-1.0E-04,2.12E-04;p>0.05), HGS (β=-1.1E-04;95%CI=-5.0E-04,2.8E-04;p>0.05), and GS (β=-5.1E-06;95%CI=-1.0E-05,2.0E-05;p>0.05) in fully adjusted models. Similarly, plasma GDF-15 was not associated with both the incidence of sarcopenia (OR=1.001,95%CI=1.000,1.002,p>0.05) and the evolution of its determinants ([ALM, β=2.1E-05;95%CI=-2.6E-04,3.03E-04;p>0.05], HGS [β=-5.9E-04;95%CI=-1.26E-03,8.1E-05; p>0.05] nor GS [β=-2.6E-06;95%CI=-3.0E-05, 2.3E-05;p>0.05]) in fully adjusted models. Blood apelin and GDF-15 were not associated with sarcopenia incidence or with the evolution of sarcopenia components over a 2-year follow-up in community-dwelling older adults. Well-powered longitudinal studies are needed to confirm or refute our findings.
Identifiants
pubmed: 35718864
doi: 10.1007/s12603-022-1800-1
doi:
Substances chimiques
Apelin
0
Growth Differentiation Factor 15
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
564-570Déclaration de conflit d'intérêts
All authors declare the absence of conflicts of interest.